Evidence Level:Sensitive: D – Preclinical
Title:
Abstract 5946: OBI-999, an anti-Globo H antibody drug conjugate, exhibits synergistic anti-tumor effect in combination with pembrolizumab
Excerpt:In the high GH expression human breast cancer cell line HCC-1428 xenograft model, OBI-999+pembrolizumab exhibited significantly stronger inhibition of tumor growth compared to either OBI-999 or pembrolizumab alone….The results suggest that combination therapy with OBI-999 and immune checkpoint inhibitors is warranted in human clinical studies.
DOI:https://doi.org/10.1158/1538-7445.AM2023-5946